Immunomedics (IMMU) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kitty2 who wrote (286)	12/18/2004 12:12:46 PM
From: idahoranch1	Read Replies (1) of 371

Little question that this has been a very frustrating investment, especially for those that have to use at least two hands to get enough fingers to count the years. Here is my abbreviated view of the bear side and the bull side. The company has been public for 20 years now and has a history of going to the public trough for money to fund it's operations and significant management salaries for the lions share of that 20 years instead of doing corporate deals which would have supplemented the cash and taken significant expenditures off their hands and accelerated the march to approvals. The Amgen deal seemed to be one that, while short on upfront money, should have gotten Epratuzumab approved and gotten the company on it's way to the ability to really push what appears to be a significant antibody pipeline. We all are quite aware that that didn't happen, and the reason for that could be the basis for plenty of discussion. But the fact remains that the company had the rights outside North America and Australia and always kept the carrot in front of us that they were looking to license those rights to someone who was always very interested. The company also presented Epratuzumab to the public in the late 1990s as an antibody that was getting results that would make it a slam dunk for approval. That turned out not to be the case. CEA-Cide was also presented as "The nuts and bolts" of the company, and they tried to leave the impression that companies were out there that would license it if only IMMU were willing. That was not likely the case either. CEA-Cide is now on the back burner. hPAM4 was presented as a very exciting product when combined with Gemcitabine for pancreatic cancer in preclinical studies and a phase l trial was supposed to be started early in 2004. To my knowledge no patients have been treated yet, and when it does start, it won't be used with Gemcitabine as it has to establish it's safety profile on it's own. CD74 is the next "exciting" carrot we will be hearing about. But, without capital, it will be slow and torturous and very costly to current shareholders, so that brings us back to CD22 (Epratuzumab). I'll post more on that and look at the bull side on my next post.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next